Loading...
In clinical trials involving patients with esophagogastric adenocarcinoma, treatments with monoclonal antibodies targeting transmembrane growth-factor receptors have largely failed. However, some trials did not use biomarkers to select patients most likely to respond to such therapy.
Investigators now report results of an industry-sponsored, international, randomized, double-blind, placebo-controlled, phase 2 trial (FIGHT) that used overexpression of fibroblast growth-factor receptor 2b (FGFR2b) or FGFR2 gene amplification to select advanced gastric cancer patients who might respond to bemarituzumab, a humanized monoclonal antibody blocking the FGFR2b receptor.
Of 910 screened participants with HER2-negative metastatic gastric or gastroesopha…